breast cancer

Overview

Breast cancer is a heterogeneous Malignant Disease arising from breast tissue, most commonly from the epithelial cells of the ducts or lobules. It is one of the most frequently diagnosed Cancers worldwide and remains a leading cause of cancer-related mortality among women, particularly because of metastatic disease, therapy resistance, and biologic diversity across subtypes. Clinically, breast cancer is often classified by hormone receptor status and other molecular features, which influence prognosis and treatment selection.

From a biomedical perspective, breast cancer is not a single entity but a spectrum of diseases shaped by tumor-intrinsic alterations and the surrounding tumor microenvironment. Recent research has emphasized pathways involving Estrogen receptor (ER) signaling, PI3K/Akt signaling, DNA damage repair, ferroptosis, cuproptosis, checkpoint inhibitor, and interactions with macrophage, dendritic cell, B-cell, and T-lymphocytes populations. These mechanisms are being explored to improve diagnosis, predict response, and overcome resistance to therapies such as paclitaxel, docetaxel, olaparib, radiation therapy, and Targeted Cancer Therapy.

Recent Publications Summary

Recent research on breast cancer encompasses diverse therapeutic strategies targeting multiple pathways. Novel drug delivery systems have shown promise, including glycoconjugate vanadyl complexes designed to exploit glucose transporter (GLUT) overexpression in cancer cells, with the CG ligand demonstrating potent cytotoxicity (IC₅₀ = 14.2 μM) in MCF-7 breast cancer cells 42601367Aug. Photodynamic therapy approaches have advanced with the development of mitochondria-targeted iridium(III) complexes that generate Type-I/II reactive oxygen species and induce pyroptosis through the caspase-3/GSDME pathway, triggering immunogenic cell death and demonstrating potent antitumor efficacy in both in vitro and in vivo models 42489638Jul. Immunotherapeutic approaches have expanded to include engineered NK and T cells expressing metabolite-sensing receptors (GPR183, GPR84, GPR34, GPR18) identified through CRISPR screens, which enhance tumor infiltration and improve tumor control in breast and ovarian cancer models 41872506Mar. Natural product extracts have also been evaluated for anticancer activity, with Inula viscosa demonstrating anti-metastatic potential in MCF-7 breast cancer cells and down-regulated autophagy-related genes 41108141Oct.

Predictive modeling has become increasingly sophisticated for stratifying breast cancer prognosis and predicting treatment response. A prognostic risk model incorporating eight programmed cell death (PCD)-related genes was developed using multivariate Cox regression analysis, enabling differentiation between high-risk and low-risk cohorts and assessment of drug sensitivity and tumor mutation burden 42499036Jul. Advanced imaging approaches combining radiomic and pathomic data with deep learning have shown strong predictive performance: a radiopathomic graph neural network system achieved AUCs of 0.89 for predicting pathologic complete response to neoadjuvant therapy 41949455Apr, while the MuTriM model integrating DCE-MRI and whole-slide pathology images predicted both recurrence and adjuvant radiation benefit 41850009Mar. Traditional imaging modalities have also been compared in this context, with dynamic contrast-enhanced MRI and 18F-FDG PET/CT parameters both demonstrating utility in predicting pathological response to neoadjuvant therapy when measured at baseline and post-treatment timepoints 40824136Aug.

Clinical management of breast cancer in the setting of comorbidities has been examined, particularly in patients with concurrent type 2 diabetes mellitus. A retrospective analysis of 104 breast cancer patients with T2DM investigated the effects of metformin use on demographic characteristics, pathological parameters, treatment response, and prognosis 42528302Jul. Pain management in breast cancer patients presenting with pre-existing chronic non-cancer pain represents another clinical challenge, as opioid prescribing patterns differ between breast cancer patients and those with lung or colorectal Cancers 42525681Jul. Supportive care has expanded to include spiritual care interventions, with an e-book designed specifically for women with breast cancer undergoing chemotherapy addressing often-overlooked spiritual needs in clinical practice 42081034May. Additionally, genetic factors may modulate treatment responses, as demonstrated in a long-term prospective study finding that the FTO rs9939609 genotype modified the association between bariatric surgery and breast cancer incidence, with surgery reducing breast cancer risk specifically in carriers of the risk allele (TA/AA, adjusted HR = 0.53) 42091990May.

Advances in diagnostic and computational approaches continue to enhance breast cancer detection and precision medicine applications. An AI-driven deep learning pipeline incorporating the Kolmogorov-Arnold Recurrent Network (KARN), optimized by the Stellar Oscillation Optimizer, achieved high accuracy in early detection and classification of breast cancer as benign or malignant from medical images, addressing key diagnostic challenges related to tissue variability and subtle abnormality interpretation 42442269Jul. computational tools supporting multi-omics integration have also expanded, with the pathMED R/Bioconductor package providing a unified framework for molecular scoring and machine learning applications using omics data to predict clinical outcomes 42496598Jul.

What Changes, What Holds

1. Engineered immune cells with metabolite-sensing receptors enhance breast cancer tumor control
NEW DIRECTION Metabolite-sensing receptors (GPR183, GPR84, GPR34, GPR18) engineered into NK and T cells were identified through CRISPR screening specifically for enhanced breast cancer infiltration and tumor control 41872506Mar. The baseline emphasizes T-lymphocyte interactions broadly but specifies no receptor engineering or metabolite-sensing strategy for immune enhancement. Photodynamic therapy with iridium complexes generating Type-I/II reactive oxygen species and triggering pyroptosis through GSDME represents an alternative death pathway 42489638Jul. Both remain preclinical; clinical comparison with checkpoint inhibitors awaits prospective trials.

2. Radiopathomic deep learning and genomic risk signatures predict complete pathological response with high accuracy
METHOD Radiopathomic graph neural networks and programmed cell death gene signatures achieve AUC 0.89 for predicting complete response to neoadjuvant therapy 41949455Apr42499036Jul. These computational advances refine the baseline's stated goal of predicting treatment response through novel measurement and analysis techniques rather than new biological mechanisms. Clinical implementation and comparative advantage over conventional imaging await prospective validation.

3. Genetic modulation of surgery's protective effect and comorbidity-specific management extend breast cancer care beyond treatment
NEW DIRECTION Bariatric surgery reduces breast cancer incidence specifically in carriers of the FTO rs9939609 risk allele 42091990May. The baseline discusses no prevention mechanisms or genetic factors influencing risk reduction, leaving this preventive angle entirely uncovered. metformin use in diabetic patients and effects on pathological parameters represent similarly unexplored clinical contexts 42528302Jul. These findings are primarily observational; prospective cohort studies would strengthen the case for clinical integration.

4. Kolmogorov-Arnold Recurrent Networks and multi-omics packages standardize computational diagnosis and molecular prediction
METHOD Deep learning incorporating Kolmogorov-Arnold Recurrent Networks achieved high accuracy in benign/malignant classification, while the pathMED R/Bioconductor package provides unified molecular scoring and machine learning for multi-omics outcome prediction 42442269Jul42496598Jul. These represent methodological innovations in how breast cancer is studied rather than new biological insights, advancing known goals of improving diagnosis and enabling precision medicine. Their clinical utility relative to existing diagnostic approaches remains unestablished.

Overview update candidates: none — all findings require clinical validation before integration into established knowledge.